TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30014661
Drug: Moxibustion combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion combined with 5‐HT receptor antagonist
Study: 22992074
Drug: Severe hypoglycemia
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe hypoglycemia without insulin treatment
Study: 19927026
Drug: Quercetin (Q;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (Q; 1000 mg x d(‐1))
Study: 16293869
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel 35 mg/m2 on days 1, 8, and 15 for < or = eight cycles
Study: 16293869
Drug: 3‐weekly docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐weekly docetaxel 75 mg/m2 on day 1 every 3 weeks for < or = eight cycles
Study: 11916776
Drug: HBOC‐201 (0.6,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBOC‐201 (0.6, 0.9, 1.2, 1.5, 2.0, or 2.5 g/kg of body weight)
Study: 7639505
Drug: Captopril +
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril + Hydrochlorothiazide (50 mg/25 mg)
Study: 30033974
Drug: Levofloxacin (LVFX)
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin (LVFX) 500 mg
Study: 17446716
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral and topical administration of lutein and zeaxanthin
Study: 17446716
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of zeaxanthin
Study: 15023936
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 8 mg (C8)
Study: 15023936
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 16 mg (C16)
Study: 11772257
Drug: Cilomilast (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilomilast (up to 15 mg)
Study: 2906863
Drug: Reinforcement for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinforcement for abstinence from illicit drug use
Study: 31762105
Drug: Intervention (integrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (integrating smoking cessation treatment into usual AOD treatment)
Study: 19745765
Drug: Figitumumab (F,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Figitumumab (F, CP-751,871) 0.05-20 mg/kg in combination with paclitaxel 200 mg/m2 and carboplatin (AUC 6) q3 weeks for up to six cycles.
Study: 19745765
Drug: Figitumumab (F,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Figitumumab (F, CP-751,871) 10 and 20 mg/kg dosing cohorts.
Study: 12891222
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (300 mL)
Study: 11174009
Drug: Captopril (112
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (112 +/- 7 mg/day)
Study: 11174009
Drug: Doxazosin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (8 +/- 1 mg/day)
Study: 9059480
Drug: CPAP at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP at 10 cm H2O at a FGF rate of 50 l/min
Study: 17484092
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg per day
Study: 18271912
Drug: Lamotrigine (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (fixed dose of 50 mg or 200 mg daily in Study 1; flexible dose of 100‐400 mg daily in Study 2; fixed dose of 200 mg daily in Studies 3, 4 and 5)
Study: 16163899
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg Iclopid tablets (test formulation)
Study: 6327600
Drug: Low-dose pivmecillinam
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose pivmecillinam for up to three months
Study: 30290983
Drug: Commercial ultrasound
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial ultrasound transmission gel (USTG)
Study: 30290983
Drug: Glucomannan gel
DrugBank: Konjac mannan (DB14963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucomannan gel
Study: 24813620
Drug: Lenalidomide 10
Normalized name: lenalidomide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 10 mg/d (days 1-21)
Study: 24813620
Drug: Lenalidomide 5
Normalized name: lenalidomide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 5 mg/d (days 1-28)
Study: 24813620
Drug: Lenalidomide 5
Normalized name: lenalidomide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 5 mg/d
Study: 21988705
Drug: Aloe vera/olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera/olive oil cream
Study: 21988705
Drug: Betamethasone 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone 0.1% cream
Study: 20152239
Drug: Aged garlic
Normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged garlic extract plus supplement
Study: 15707855
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 100 mg once daily for 72 hours
Study: 15707855
Drug: IV hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV hydrocortisone 100 mg every 6 hours for 72 hours
Study: 7284649
Drug: Phenytoin 300
Normalized name: phenytoin 300 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin 300 mg per day for two weeks
Study: 27836430
Drug: Monthly dosing
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly dosing with ranibizumab 0.3 mg every 4 weeks
Study: 2088768
Drug: Romazarit (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romazarit (single oral doses ranging from 40 to 1500 mg)
Study: 2088768
Drug: Placebo (capsules)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (capsules)
Study: 28644761
Drug: Satir communication
Normalized name: Vagisil Satin
DrugBank: Hydrocortisone acetate (DB14539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Satir communication family therapy (CFT), 7 sessions
Study: 23435190
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A (0.5% AR-12286 Ophthalmic Solution) once daily, both eyes for 8 days
Study: 23435190
Drug: Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation B (0.5% AR-12286 Ophthalmic Solution) once daily, both eyes for 8 days
Study: 17627241
Drug: Single 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 9 mg/kg dose antithymocyte globulin (ATG)
Study: 17627241
Drug: Two 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 20 mg doses of basiliximab
Study: 12738159
Drug: Rectal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal misoprostol 600 microg
Study: 23464658
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia with propofol and remifentanil (TIVA)
Study: 19342206
Drug: Zolmitriptan 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan 7.5 mg/d
Study: 15377579
Drug: Ropivacaine 2
Normalized name: fentanyl-ropivacaine 2 mcg/mL-0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 2 mg ml(‐1) and fentanyl 5 microg ml(‐1) without clonidine (Group RF)
Study: 9702404
Drug: Intraperitoneal postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal postoperative treatment
Study: 22092477
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity laser therapy (LILT) applied with a diode laser (588 nm) before and immediately after surgery, and for 5 min daily for 7 days post-operatively
Study: 18400982
Drug: Transdermal methylphenidate
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal methylphenidate
Study: 17701685
Drug: Chronotherapeutic strategies
Normalized name: Other chemotherapeutics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronotherapeutic strategies (timed administration of antihypertensive medication)
Study: 31693129
Drug: Oral clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clodronate
Study: 12202673
Drug: Intravenous pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pamidronate or zoledronic acid
Study: 10701819
Drug: Trandolapril 2
Normalized name: trandolapril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 2 mg once daily
Study: 2283644
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg once daily
Study: 17084621
Drug: Sequential chemo-radiotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemo-radiotherapy
Study: 31785830
Drug: Sequential chemo-radiotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemo-radiotherapy (anthracycline-CMF subgroup)
Study: 16213322
Drug: Calcitriol therapy
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol therapy (group 1, n = 57)
Study: 12165477
Drug: Anticholinergic drug
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic drug (0.4 mg iv scopolamine)
Study: 9885795
Drug: ipsapirone (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipsapirone (0.3 mg/kg)
Study: 2044333
Drug: Flumazenil infusion
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumazenil infusion at 10 micrograms/L
Study: 21127282
Drug: Midazolam infusion
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam infusion
Study: 30797389
Drug: Happiness exercises
Normalized name: Happy Cappy
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Happiness exercises (5 brief self-administered exercises)
Study: 9492719
Drug: Methylergometrine 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylergometrine 0.125 mg three times a day for three days
Study: 23103596
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol hydrochloride 25 mg
Study: 29221795
Drug: Lidocaine hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine hydrochloride 20 mg
Study: 28564127
Drug: Terlipressin (1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (1-4 μg/kg/h) for 5 days
Study: 10686803
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of lisinopril (32.5-35 mg/daily)
Study: 10686803
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of lisinopril (2.5-5 mg/daily)
Study: 1912370
Drug: Bestatin immunotherapy
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bestatin immunotherapy
Study: 31538590
Drug: Placebo (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (400 mg corn oil daily for 180 days)
Study: 16412747
Drug: Oral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen therapy (0.625 mg of conjugated equine E per tablet; n = 27)
Study: 16412747
Drug: Topical estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical estrogen therapy (0.625 mg conjugated equine E per 1 g vaginal cream; n = 30)
Study: 8546117
Drug: Oral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen therapy
Study: 16412747
Drug: Topical estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical estrogen therapy
Study: 9690480
Drug: Placebo following
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo following a 1-week LMWH treatment (once daily)
Study: 3319640
Drug: Nicardipine 30
Normalized name: niCARdipine 30 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 30 mg t.d.s.
Study: 3319640
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg t.d.s.
Study: 27403851
Drug: l-Tyrosine (TYR)
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: l-Tyrosine (TYR) supplementation
Study: 24604243
Drug: Almorexant 100
Normalized name: Nemorexant
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Almorexant 100 mg
Study: 26734954
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (230 ml/day for women, 300 ml/day for men)
Study: 22848584
Drug: Psyllium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium supplementation (6 g/day for 6 weeks)
Study: 16045013
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg/d) + Benazepril (10 mg/d)
Study: 8841148
Drug: Quinidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (200 mg)
Study: 7480098
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nifedipine (20 mg) and quinidine (200 mg)
Study: 2110817
Drug: Non-sedative antihistamine
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-sedative antihistamine terfenadine (60 mg b.i.d.)
Study: 2110817
Drug: Sedative antihistamine
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative antihistamine clemastine (2 mg b.i.d.)
Study: 29349922
Drug: Breast milk
Normalized name: BREAST MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast milk intake at 9-10 months of age (mean 752 g/day)
Study: 27225338
Drug: 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg magnesium sulfate via cardioplegic solution
Study: 27225338
Drug: 100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/kg magnesium sulfate via cardioplegic solution
Study: 27225338
Drug: 80 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/kg and 100 mg/kg magnesium sulfate
Study: 20403667
Drug: Late enteral
Normalized name: Soy protein isolate enteral formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late enteral nutrition (LEN) group, received only intravenous resuscitation in the first 48 hours
Study: 30048979
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no metformin)
Study: 7519032
Drug: 1,24(OH)2D3 ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,24(OH)2D3 ointment (tacalcitol; 4 micrograms/g)
Study: 2928741
Drug: Clonidine 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.075 mg twice daily
Study: 1410124
Drug: Alcohol (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (high dose: 1.1 ml. ethanol/kilogram body weight)
Study: 648938
Drug: Cimetidine treatment
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine treatment for 12 weeks
Study: 26319612
Drug: biofortified gari
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: biofortified gari (1 mg β‐carotene)
Study: 26319612
Drug: unfortified gari
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: unfortified gari (0.3 mg retinyl palmitate reference dose)
Study: 20644943
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg q.d.
Study: 20644943
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 100 mg q.d.
Study: 16458133
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ASA and clopidogrel
Study: 17589944
Drug: Chemoradiation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation therapy (gemcitabine and radiation dose 50.4 Gy) before surgery
Study: 15140780
Drug: PVAC (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVAC (50 micro g)
Study: 2675439
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg chlorophyll tablets thrice daily
Study: 1089971
Drug: Synthetic luteinizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic luteinizing hormone-releasing hormone (LH-RH) 50 μg
Study: 1089971
Drug: Synthetic luteinizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic luteinizing hormone-releasing hormone (LH-RH) 100 μg
Study: 1089971
Drug: Two injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two injections of LH-RH 90 min apart
Study: 1089971
Drug: Two injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two injections of LH-RH 30 or 45 min apart
Study: 1089971
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of LH-RH (not specified)
Study: 20579847
Drug: Fructo-oligosaccharides (FOS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructo-oligosaccharides (FOS) 10 g/d
Study: 19279365
Drug: CDC model
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDC model early stimulation therapy (home-based)
Study: 15033892
Drug: Fentanyl 5
Normalized name: fentanyl 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 5 microg ml(‐1) in bupivacaine 0.1%
Study: 15033892
Drug: Fentanyl 10
Normalized name: FENTANYL 100MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 10 microg ml(‐1) in bupivacaine 0.1%
Study: 14597359
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam radiation therapy
Study: 9587125
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy for metastatic disease
Study: 9587125
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with doxorubicin-containing regimens
Study: 7725890
Drug: Diclofenac 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 1.0 mg.kg‐1 i.v. after general anaesthesia induction, before surgical incision, and four hours later the same dose was given i.m.
Study: 7725890
Drug: Ketoprofen 1.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 1.35 mg.kg‐1 i.v. and i.m.
Study: 7028759
Drug: Multi-drug chemotherapy
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-drug chemotherapy with local radiotherapy (5-FU and local radiotherapy to a dose of 4600 rad, then Methyl-CCNU)
Study: 7028759
Drug: Multi-drug chemotherapy
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-drug chemotherapy without radiotherapy (5-FU and Methyl-CCNU)
Study: 7028759
Drug: Multi-drug chemotherapy
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-drug chemotherapy with local radiotherapy
Study: 7028759
Drug: Multi-drug chemotherapy
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-drug chemotherapy without radiotherapy
Study: 29127417
Drug: Xueshuan Xinmai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xueshuan Xinmai tablets (XXMT)
Study: 18394772
Drug: Nifedipine gastrointestinal
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine gastrointestinal therapeutic system (GITS) tablets (90 mg/d)
Study: 15744147
Drug: Non-viral IL-2
Normalized name: IL-3 (NON-GLYCOSYLATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-viral IL-2 gene therapy
Study: 15744147
Drug: Control plasmid
Normalized name: plasmin
DrugBank: Fibrinolysin (DB05254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control plasmid in cationic lipid formulation
Study: 15744147
Drug: Methotrexate chemotherapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate chemotherapy
Study: 10568212
Drug: DHEP gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEP gel
Study: 9082374
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg/d)
Study: 8453465
Drug: Oral response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral response mode
Study: 27681572
Drug: TAU plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU plus four 2.5-h weekly sessions of theory-based lifestyle structured group education, maintenance contact every 2 weeks, and 'booster' sessions every 3 months.
Study: 17445284
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g low molecular weight (LMW) BBG
Study: 17445284
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g high molecular weight (HMW) BBG
Study: 17445284
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g low molecular weight (LMW) BBG
Study: 17445284
Drug: TAG (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAG (all treatment groups)
Study: 1885426
Drug: Acyclovir 400
Normalized name: acyclovir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 400 mg twice daily for five days
Study: 1885426
Drug: Acyclovir 200
Normalized name: acyclovir 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 200 mg twice a day for five days
Study: 21681516
Drug: Dienogest (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dienogest (2 mg once daily, orally)
Study: 19349517
Drug: Nikkomycin Z
Normalized name: Nikkomycin Z
DrugBank: Nikkomycin Z (DB12939)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nikkomycin Z (all doses)
Study: 17484872
Drug: severe recurrence
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: severe recurrence treatment (group C)
Study: 17484872
Drug: treatment (overall)
Normalized name: Hongo Killer Treatment
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment (overall)